PPT-Fostemsavir in Treatment-Experienced Patients

BRIGHTE Study Week 48 Data Fostemsavir FTR for Heavily Treatment Experienced BRIGHTE Study Week 48 Background Source Kozal M et al N Engl J Med 2020382123243 Study Design BRIGHTE. thalassaemia. . Where . are we now?. Telaprevir . and . boceprevir. harbingers . of important . treatment advance. Improved response rates . observed : . naive . and . experienced patients. SVR > 70. SIRIUS. Phase . 2 . Treatment. . Experienced. Bourliere. M, et al. Lancet Infect Dis. . 2015;15:397-404.. Source: . Bourliere. . M, . et al. . Lancet Infect Dis. 2015;15:397-404.. Ledipasvir-Sofosbuvir in Treatment-Experienced . Susan M. Graham . Assistant Professor, Medicine and Global Health. Adjunct Assistant Professor, Epidemiology. Presentation prepared by: . Susan M. Graham. Last Updated: . October 29, 2014. Susan M. Graham, MD MPH PhD. Advanced Malignancies. METHODS. DISCUSSION. RESULTS. . ACKNOWLEGEMENTS. . BACKGROUND. Current approaches in the treatment of advanced cancer are based predominantly upon lessons learned from the cytotoxic era. Our current approaches have yielded incremental steps forward, but most patients who develop metastatic disease still die and the costs of care are . . or 3 . LONESTAR-2. Phase 2. Treatment. . Experienced. Lawitz. . E, et al. . Hepatology. . 2015:61:769-75.. Source: . Lawitz. E, et al. . Hepatology. . . 2015:61:769-75.. Sofosbuvir + . PEG + RBV . Interim Analysis of a French Multicenter Compassionate Use Program. Christophe Hézode,. 1. Victor De Ledinghen,. 2. Helene Fontaine,. 3. Fabien Zoulim,. 4. Pascal Lebray,. 5. Nathalie Boyer,. 6. When should it be done?. Professor of Medicine. UNC Chapel Hill School of Medicine. Joseph J. Eron, Jr., MD. Disclosures. Principal Investigator (Research Grants to University of North Carolina): GlaxoSmithKline/. Prof. G. K. K. Lau 2012. Standard of care (SOC) for chronic HCV infection. Peginterferon. (. PegIFN. ) + ribavirin (RBV). 48 weeks (HCV G1, 4, 5 and 6). 24 weeks (HCV G2 and 3). Induce sustained . Erik R. Timmermans Remco J. Renken Gert J. Ter Horst Anna K.L. Reyners Published in Nutrition and Cancer Metallic taste in cancer patients treated with systemic therapy: a questionnaire-based study Lopinavir. -RTV in Treatment Experienced. TITAN Trial. Darunavir/. r . versus Lopinavir/r in Treatment-Experienced . TITAN. : Study Design. Source: . Madruga. JV, et al. Lancet. 2007;370:49-58. . Darunavir. Prepared by:. Brian R. Wood, MD. David H. Spach, MD. Last Updated: January 28, 2021. Dolutegravir (. Tivicay. ) . INSTI. Tivicay. . [TIV-eh-kay]. Dolutegravir. Treatment Naïve. : 50 mg once daily with or without food. POTENT Trial. Tipranavir. /. r . versus Darunavir. /r . in Treatment-Experienced . POTENT. : Study Design. Source: . Elgadi. MM, et al. . Drugs R D. . 2011;11:. 295-. 302.. Tipranavir. . + . R. itonavir BID . POWER 1 and 2. Darunavir. /. r versus other PIs in Treatment-Experienced . POWER 1 and 2. : Study Design. Source: . Clotet. B, et al. . Lancet. . 2007;369:. 1169-78.. Darunavir BID + RTV BID + OBR . HIV-NAT . 017. SQV and . LPV-RTV . in Treatment-Experienced Children . HIV-NAT . 017: . Study . Design. Source: . Kosalaraksa. P, et al. . Pediatr. Infect Dis J. . 2008;27:. 623-8. . SQV + LPV-RTV +/- 3TC.